U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06899906) titled 'Efficacy and Safety of Dalbavancin As Suppressive Therapy' on March 21.
Brief Summary: Dalbavancin (DAL) is a semi-synthetic antibiotic that belongs to the lipoglycopeptide family and is structurally derived from teicoplanin, respect of which it has two structural differences that enhance its anti-staphylococcal binding affinity and extend its half-life to between 149 and 250 hours. It achieves adequate tissue penetration in the skin, bones, joints, lung tissues, and peritoneal space, maintaining concentrations above the MIC for susceptible Gram-positive pathogen.
DAL is a bactericidal antimicrobial agent that binds the C-terminal...